JP2020524139A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524139A5
JP2020524139A5 JP2019569312A JP2019569312A JP2020524139A5 JP 2020524139 A5 JP2020524139 A5 JP 2020524139A5 JP 2019569312 A JP2019569312 A JP 2019569312A JP 2019569312 A JP2019569312 A JP 2019569312A JP 2020524139 A5 JP2020524139 A5 JP 2020524139A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
subject
composition according
myelofibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569312A
Other languages
English (en)
Japanese (ja)
Other versions
JP7496686B2 (ja
JP2020524139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037213 external-priority patent/WO2018231905A1/en
Publication of JP2020524139A publication Critical patent/JP2020524139A/ja
Publication of JP2020524139A5 publication Critical patent/JP2020524139A5/ja
Priority to JP2024027645A priority Critical patent/JP2024075579A/ja
Application granted granted Critical
Publication of JP7496686B2 publication Critical patent/JP7496686B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569312A 2017-06-14 2018-06-13 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 Active JP7496686B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024027645A JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762519725P 2017-06-14 2017-06-14
US62/519,725 2017-06-14
US201862679210P 2018-06-01 2018-06-01
US62/679,210 2018-06-01
PCT/US2018/037213 WO2018231905A1 (en) 2017-06-14 2018-06-13 Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024027645A Division JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Publications (3)

Publication Number Publication Date
JP2020524139A JP2020524139A (ja) 2020-08-13
JP2020524139A5 true JP2020524139A5 (cg-RX-API-DMAC7.html) 2021-07-29
JP7496686B2 JP7496686B2 (ja) 2024-06-07

Family

ID=64660712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019569312A Active JP7496686B2 (ja) 2017-06-14 2018-06-13 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
JP2024027645A Pending JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024027645A Pending JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Country Status (16)

Country Link
US (1) US20200101134A1 (cg-RX-API-DMAC7.html)
EP (2) EP4454707A3 (cg-RX-API-DMAC7.html)
JP (2) JP7496686B2 (cg-RX-API-DMAC7.html)
CN (1) CN111050770A (cg-RX-API-DMAC7.html)
DK (1) DK3638243T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991738T3 (cg-RX-API-DMAC7.html)
FI (1) FI3638243T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241477T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068733T2 (cg-RX-API-DMAC7.html)
LT (1) LT3638243T (cg-RX-API-DMAC7.html)
PL (1) PL3638243T3 (cg-RX-API-DMAC7.html)
PT (1) PT3638243T (cg-RX-API-DMAC7.html)
RS (1) RS66093B1 (cg-RX-API-DMAC7.html)
SI (1) SI3638243T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400437T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018231905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
CA3043184A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
IL278546B2 (en) 2018-05-09 2026-03-01 Keros Therapeutics Inc Activin receptor type IIA variants and methods of using them
JP7663502B2 (ja) * 2018-10-31 2025-04-16 セルジーン コーポレイション 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン-actriiリガンドトラップを用いた治療
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
US20230181690A1 (en) * 2020-04-13 2023-06-15 Celgene Corporation Methods for treating anemia using an actriib ligand trap and fedratinib
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
CA3177632A1 (en) * 2020-05-15 2021-11-18 Melih ACAR Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
WO2022271716A2 (en) * 2021-06-21 2022-12-29 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
EP4387737A4 (en) * 2021-08-19 2025-06-18 Keros Therapeutics, Inc. METHODS OF USING INHIBITORS OF ACTIVIN RECEPTOR TYPE II SIGNALING
WO2025137373A1 (en) * 2023-12-19 2025-06-26 Cellarity, Inc. Disease detection systems and methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
DK3520805T3 (da) 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ, インコーポレイテッド アクチビンbおよび/またはgdf11の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
JP7072507B2 (ja) * 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
LT3490582T (lt) * 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę

Similar Documents

Publication Publication Date Title
Kuriyam et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
Gimenez et al. TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation
JP6887212B2 (ja) Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2020183389A5 (cg-RX-API-DMAC7.html)
US20110152192A1 (en) Compositions and Methods for the Treatment of Angiogenesis-Related Eye Diseases
FI3638243T3 (fi) Menetelmiä myeloproliferatiivin neoplasma-assosioidun myelofibroosin ja anemian hoitamiseksi
CN116261463A (zh) 治疗痛风的方法
US20250188158A1 (en) Treatment of Parkinson's Disease
TW202432135A (zh) 藉由投予(r)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑並[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-氧雜環丁-3-基)哌𠯤-1-基]戊-2-烯腈治療免疫性血小板減少症的方法
WO2023122355A2 (en) Methods of treating or preventing infusion-related reactions
CN107106645A (zh) 用于治疗c‑met相关性癌症的方法和组合物
US20230151107A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
CN113631181A (zh) 度拉糖肽的治疗用途
AU2022358509A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome
ES2880950T3 (es) Terapia de anticuerpos contra el VIH como sustituto del tratamiento
AU2018228246A1 (en) Preventive or therapeutic agent for HTLV-1-associated myelopathy using low-dose anti-CCR4 antibody
JP2023523568A5 (cg-RX-API-DMAC7.html)
TW202440120A (zh) 藉由投予(r)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]六氫吡啶-1-羰基]-4-甲基-4-[4-(氧雜環丁-3-基)六氫吡𠯤-1-基]戊-2-烯腈治療患有認知障礙的個體之免疫性血小板減少症之方法
Mekahli et al. FC 130 Randomized, Placebo-Controlled, Phase 3b Trial of Tolvaptan in the Treatment of Children and Adolescents with autosomal Dominant Polycystic Kidney Disease (ADPKD): 1-Year Data
US11434270B2 (en) Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein
RU2848183C1 (ru) Лечение болезни паркинсона
CN108992660A (zh) 人sDR5-Fc重组融合蛋白作为胰腺炎治疗药物的应用
WO2025223394A1 (en) Combination therapy for classic hodgkin's lymphoma
Neroeva et al. Features of local expression of genes of immune response cytokines and trophic and vasoregulatory factors in modeling of retinal pigment epithelium atrophy
US20240148827A1 (en) Methods and Compositions for Treatment of Disease